HOME >> BIOLOGY >> NEWS
New Hope On The Horizon For Patients With End-Stage Cardiovascular Disease

LOS ANGELES (August 3, 1998) -- Two experimental protocols are now available at Cedars-Sinai Medical Center for patients who have undergone multiple angioplasties or bypass procedures for coronary artery disease. Both procedures are non-surgical and show promise of improving quality of life for patients with end-stage cardiovascular disease. "The preliminary data are very encouraging," says P.K. Shah, M.D., Director of Cardiology at Cedars-Sinai.

Percutaneous Transmyocardial Laser Revascularization (PTMR)
According to Dr. Shah, Cedars-Sinai is one of only a few sites in the nation to offer Percutaneous Transmyocardial Laser Revascularization (PTMR). Using this procedure, cardiologists insert a laser catheter into the heart, creating multiple channels from the inside of the heart, out. These channels improve blood flow to heart muscles and stimulate growth of new blood vessels. To date, four patients have undergone PTMR at Cedars-Sinai. Norman Lepor, M.D., is the Principal Investigator on this study.

Vascular Endothelial Growth Factor Therapy (VEGF)
The second experimental protocol is Vascular Endothelial Growth Factor (VEGF) Therapy. VEGF is a genetically engineered compound that is normally produced in small amounts by the body and stimulates blood vessel growth. In this procedure, it is injected directly into the coronary artery to further stimulate blood vessel growth. The initial injection is followed by a series of three intravenous infusions -- one every three days. These subsequent infusions are done on an outpatient basis and take about four hours each. To date, two patients have been treated with VEFG Therapy at Cedars-Sinai. Dr. Shah is the Principal Investigator on this study.

# # #

To arrange an interview, please call 1-800-396-1002. Reporters, please note that this telephone number is exclusively for media use. Thank you for not publishing it.


'"/>

Contact: Sandy Van or Roberta Nichols
sandy@vancommunications.com
1-800-396-1002
Cedars-Sinai Medical Center
3-Aug-1998


Page: 1

Related biology news :

1. Bacteria Becoming Increasingly Resistant To Antibiotics, But New Vaccines Are On The Horizon
2. Patients cells from tumors, the immune system merged for customized cancer therapy
3. Patients give nod to kidney dialysis at home
4. Patients with atrial fibrillation undertreated for stroke risk
5. Patients with serious kidney disorder produce natriuretic peptides at above average rates
6. Drug treatment interruptions boost immune response to HIV in Patients
7. Study Suggests Vaccine Increases Survival In Ovarian And Breast Cancer Patients Following High-Dose Chemotherapy And Autologous Stem Cell Transplant
8. GenRISK Genetic Testing Program At Cedars-Sinai Medical Center Offers Patients New Hope In Confronting Disease
9. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
10. In Colorado States Veterinary Foal Care Program, Student Volunteers Provide All-Night Care For Sick And Very Needy Patients
11. AIDS Virus May Evolve Differently In Cerebrospinal Fluid Compared With Blood In Some Patients, UCSF/Gladstone Research Finds

Post Your Comments:
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... DUBLIN , May 20, 2015 Research ... announced the addition of the "2015 Global ... to their offering. The primary goal ... of flow cytometry instruments and reagents. Key information ... drive the selection of flow cytometers, predominantly used ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
Cached News: